利用NSCLC患者ROSE细胞学制片进行EGFR、KRAS、PIK3CA基因检测可行性的研究

目的 探讨应用 xTAG70plex 液相芯片技术对非小细胞肺癌（NSCLC）患者的快速现场评价（ROSE）细胞学制片进行 EGFR、KRAS 和 PIK3CA 基因检测的可行性及其临床价值。方法 纳入就诊于天津医科大学总医院行支气管镜检查并最终病理诊断为 NSCLC 的患者 75 例 ROSE 细胞学制片和配对的组织学标本，分别用 xTAG70plex 液相芯片进行 EGFR、KRAS 和 PIK3CA 基因突变检测。结果 除 1 例在组织学标本检出为 KRAS 突变而在配对的ROSE 细胞学标本没有检测出来的病例，其他病例基因突变检测结果均相同，两种标本 EGFR 基因突变检测结果一 致率为 100%，KRAS 基因突变检测结果一致率为 98.7%。结论 xTAG70plex 液相芯片技术可以有效地检测 ROSE细胞学制片 EGFR、KRAS 和 PIK3CA 的基因突变状态，对于 NSCLC 患者，ROSE 细胞学制片可以作为组织学替代标本进行基因检测。

The study of the feasibility of detecting EGFR,KRAS and PIK3CA genes by ROSE cytological slides in non-small cell lung cancer

Objective To explore the feasibility of EGFR, KRAS and PIK3CA mutation analysis on rapid on-site evaluation (ROSE) cytological slides in patients with non-small cell lung cancer and its clinical value. Methods Seventy-five cases of ROSE cytological slides and paired histological specimens were collected in Tianjin Medical University General Hospital. xTAG70plex liquidchip technology was used to analyze the gene mutations of the samples. Results The KRAS mutation was found in histological specimen but not in ROSE cytological slides in one case. The mutation results were the same in histological specimen and ROSE cytological slides in other cases. The consistent rates of the EGFR mutation and KRAS mutation were 100% and 98.7%, respectively. Conclusion Our study demonstrates that xTAG70plex liquidchip technology can be used for the mutation analysis of EGFR, KRAS and PIK3CA genes in non-small cell lung cancer on ROSE cytological slides.